DS 4824

Drug Profile

DS 4824

Latest Information Update: 27 Dec 2000

Price : $50

At a glance

  • Originator Santen Pharmaceutical
  • Developer Daiichi Pharmaceutical; Santen Pharmaceutical
  • Class Antiarrhythmics
  • Mechanism of Action Potassium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arrhythmias

Most Recent Events

  • 27 Dec 2000 Discontinued-II for Arrhythmias in Japan (PO)
  • 16 Nov 2000 No-Development-Reported for Arrhythmias in Japan (PO)
  • 23 Jun 1995 Phase-II clinical trials for Arrhythmias in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top